Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
- CNW Group - Fri Sep 11, 4:15PM CDT
CNW Group - CMTX
Fri Sep 11, 4:15PM CDT
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
IIROC Trading Halt - TRIL
- PR Newswire - Fri Mar 20, 9:33AM CDT
PR Newswire - PRNW
Fri Mar 20, 9:33AM CDT
TORONTO , March 20, 2020 /CNW/ - The following issues have been halted by IIROC:
IIROC Trade Resumption - TRIL
- PR Newswire - Fri Feb 28, 11:49AM CST
PR Newswire - PRNW
Fri Feb 28, 11:49AM CST
TORONTO , Feb. 28, 2020 /CNW/ - Trading resumes in:
IIROC Trade Resumption - TRIL
- PR Newswire - Fri Feb 28, 10:58AM CST
PR Newswire - PRNW
Fri Feb 28, 10:58AM CST
TORONTO , Feb. 28, 2020 /CNW/ - Trading resumes in:
IIROC Trading Halt - TRIL
- PR Newswire - Fri Feb 28, 10:55AM CST
PR Newswire - PRNW
Fri Feb 28, 10:55AM CST
TORONTO , Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:
IIROC Trade Resumption - TRIL
- PR Newswire - Fri Feb 28, 9:06AM CST
PR Newswire - PRNW
Fri Feb 28, 9:06AM CST
TORONTO , Feb. 28, 2020 /CNW/ - Trading resumes in:
IIROC Trading Halt - TRIL
- PR Newswire - Fri Feb 28, 9:01AM CST
PR Newswire - PRNW
Fri Feb 28, 9:01AM CST
TORONTO , Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:
IIROC Trade Resumption - TRIL
- PR Newswire - Tue Oct 22, 8:13AM CDT
PR Newswire - PRNW
Tue Oct 22, 8:13AM CDT
TORONTO , Oct. 22, 2019 /CNW/ - Trading resumes in:
Trillium Therapeutics Reports First Quarter 2019 Financial Results
GlobeNewswire - Mon May 13, 6:01AM CDT
GlobeNewswire - CMTX
Mon May 13, 6:01AM CDT
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the three months ended March 31, 2019.
Trillium Announces Management and Board Changes and Provides Corporate Update
GlobeNewswire - Tue Apr 30, 6:00AM CDT
GlobeNewswire - CMTX
Tue Apr 30, 6:00AM CDT
Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive management team, its board of directors and provides an operational update.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies